Table 1 Characteristics of all patients included in the study (n = 163), comparison of these characteristics according to ELR (cut-off ≥ 0.1) and ENLR (cut-off ≥ 0.5)
Patients’ characteristics | All patients included (n = 163, % of total) | ELR < 0.1 n = 117 (%) | ELR ≥ 0.1 n = 46 (%) | p-value* | ENLR < 0.5 n = 118 (%) | ENLR ≥0.5 n = 45 (%) | p-value* |
|---|---|---|---|---|---|---|---|
Age at diagnosis (years): | |||||||
< 65 years: | 74 (45.4%) | 4 (73.0%) | 20 (27.0) | .757 | 53 (71.6%) | 21 (28.4%) | .410 |
≥ 65 years: | 89 (54.6%) | 63 (70.8%) | 26 (29.2) | 65 (73.0%) | 24 (27.0%) | ||
FIGO 2009 stage at diagnosis: | |||||||
• IA | 4 (26.0%) | 34 (7.1%) | 9 (0.9%) | .070 | 33 (76.7%) | 10 (23.3%) | .136 |
• IB | 54 (33.2%) | 33 (61.1%) | 21(38.9%) | 35 64.8%) | 19 (35.2%) | ||
• II | 24 (14.0%) | 19 (79.2%) | 5 (20.8%) | 18 (75.0%) | 6 (25.0%) | ||
• IIIA | 9 (5.5%) | 4 (44.4%) | 5 (55.6%) | 5 (55.6%) | 4 (44.4%) | ||
• IIIB | 0 | 0 | 0 | 0 | 0 | ||
• IIIC1 | 15 (9.2%) | 13 (86.7%) | 2 (13.3%) | 14 (93.3%) | 1 (6.7%) | ||
• IIIC2 | 7 (4.3%) | 7(100%) | 0 | 7 (100%) | 0 | ||
• IVA | 9 (5.5%) | 6 (66.7%) | 3 (33.3%) | 5 (55.6%) | 4 (44.4%) | ||
• IVB | 2 (1.2%) | 1 (50%) | 1 (50%) | 1 (50.0%) | 1 (50.0%) | ||
Patients in advanced stage (FIGO I-II vs. FIGO III-IV) (n,%): | |||||||
No (FIGO I-II) | 121(74.2%) | 85 (70.2%) | 36(29.8%) | .461 | 85 (70.2%) | 36 (29.8%) | .299 |
Yes (FIGO III-IV) | 42 (25.8%) | 32 (76.2%) | 10(23.8%) | 33 (78.6%) | 9 (21.4%) | ||
Tumour grade (n,%): | |||||||
1 | 36 (22.1%) | 24 (66.7%) | 12(33.3%) | .736 | 26 (72.2%) | 10 (27.8%) | .772 |
2 | 61 (37.4%) | 45 (73.8%) | 16(26.2%) | 46 (75.4%) | 15 (24.6%) | ||
3 | 66 (40.5%) | 48 (72.7%) | 18(27.3%) | 46 (69.7%) | 20 (30.3%) | ||
Patients with tumour grade 3 vs. tumour grade 1–2 (n,%): | |||||||
Grade 1–2 | 97 (59.5%) | 66 (68.0%) | 31(32.0%) | .865 | 72 (74.2%) | 25 (25.8%) | .593 |
Grade 3 | 66 (40.5%) | 46 (69.7%) | 20(30.3%) | 46 (69.7%) | 20 (30.3%) | ||
Tumour histology (n,%): | |||||||
Endometrioid | 119 (73%) | 85 (71.4%) | 34(28.6%) | .305 | 87 (73.1%) | 32 (26.9%) | .424 |
Serous-papillary | 14 (8.6%) | 12 (85.7%) | 2 (14.3%) | 10 (71.4%) | 4 (28.6%) | ||
Clear cell | 5 (3.1%) | 5 (100%) | 0 | 5 (100%) | 0 | ||
Squamous | 6 (3.7%) | 3 (50.0%) | 3 (50.0%) | 3 (50.0%) | 3 (50.0%) | ||
Villoglandular | 2 (1.2%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | ||
Sarcoma (not LMS or carcinosarcoma) | 2 (1.2%) | 2 (100%) | 0 | 2 (100%) | 0 | ||
Leiomyosarcoma | 3 (1.8%) | 1 (33.3%) | 2 (66.7%) | 1 (33.3%) | 2 (66.7%) | ||
Carcinosarcoma | 12 (7.4%) | 8 (66.7%) | 4 (33.3%) | 9 (75.0%) | 3 (25.0%) | ||
Lymphadenectomy (n,%): | |||||||
No | 29 (17.8%) | 19 (65.6%) | 10(34.5%) | .409 | 19 (65.5%) | 10 (34.5%) | .361 |
Yes | 134 (82.2%) | 98 (73.1%) | 36(26.9%) | 99 (73.9%) | 35 (26.1%) | ||
ESMO-ESGO-ESTRO (ESMO 2015) risk groups (n,%): | |||||||
1 - Low | 28 (17.2%) | 21 (75.0%) | 7 (25.0%) | .775 | 21 (75.0%) | 7 (25.0%) | .440 |
2 - Intermediate | 31 (19.0%) | 20 (64.5%) | 11(35.5%) | 21 (67.7%) | 10 (32.3%) | ||
3- High-Intermediate | 13 (8.0%) | 9 (69.2%) | 4 (30.8%) | 8 (61.5%) | 5 (38.5%) | ||
4 - High | 75 (46.0%) | 57 (76.0%) | 18(24.0%) | 59 (78.7%) | 16 (21.3%) | ||
5 - Advanced | 14 (8.6%) | 9 (64.3%) | 5 (35.7%) | 8 (57.1%) | 6 (42.9%) | ||
6 - Metastatic | 2 (1.2%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | ||
Patients in high-risk groups according to ESMO-ESGO-ESTRO risk classification (n,%): | |||||||
Low (risk group 1–3) | 72 (44.2%) | 47 (65.3%) | 25(34.7%) | .496 | 50 (69.4%) | 22 (30.6%) | .484 |
High (risk group 4–6) | 91 (55.8%) | 65 (71.4%) | 26(28.6%) | 68 (74.7%) | 23 (25.3%) | ||
Brachytherapy exclusive (n,%): | |||||||
No | 110 (67.5%) | 75 (68.2%) | 35(31.8%) | .142 | 77 (70.0%) | 33 (30.0%) | .325 |
Yes | 53 (32.5%) | 42 (79.2%) | 11(20.8%) | 41 (77.4%) | 12 (22.6%) | ||
Chemotherapy (n,%): | |||||||
No | 104 (63.8%) | 72 (69.2%) | 32(30.8%) | .337 | 71 (68.3%) | 33 (31.7%) | .118 |
Yes | 59 (36.2%) | 45 (76.3%) | 14(23.7%) | 47 (79.7%) | 12 (20.3%) | ||